87 related articles for article (PubMed ID: 9351367)
1. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport.
Jin FY; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2020-8. PubMed ID: 9351367
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance.
Liao D; Tan H; Hui R; Li Z; Jiang X; Gaubatz J; Yang F; Durante W; Chan L; Schafer AI; Pownall HJ; Yang X; Wang H
Circ Res; 2006 Sep; 99(6):598-606. PubMed ID: 16931800
[TBL] [Abstract][Full Text] [Related]
3. A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity.
Seckler HDS; Fornelli L; Mutharasan RK; Thaxton CS; Fellers R; Daviglus M; Sniderman A; Rader D; Kelleher NL; Lloyd-Jones DM; Compton PD; Wilkins JT
J Proteome Res; 2018 Jun; 17(6):2156-2164. PubMed ID: 29649363
[TBL] [Abstract][Full Text] [Related]
4. Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.
Tang J; Li D; Drake L; Yuan W; Deschaine S; Morin EE; Ackermann R; Olsen K; Smith DE; Schwendeman A
J Lipid Res; 2017 Jan; 58(1):124-136. PubMed ID: 27881716
[TBL] [Abstract][Full Text] [Related]
5. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.
Moradi H; Said HM; Vaziri ND
Transl Res; 2013 Jun; 161(6):477-85. PubMed ID: 23219399
[TBL] [Abstract][Full Text] [Related]
6. Characterization of endocytic compartments after holo-high density lipoprotein particle uptake in HepG2 cells.
Röhrl C; Pagler TA; Strobl W; Ellinger A; Neumüller J; Pavelka M; Stangl H; Meisslitzer-Ruppitsch C
Histochem Cell Biol; 2010 Mar; 133(3):261-72. PubMed ID: 20039053
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.
Zamanian-Daryoush M; Lindner DJ; Buffa J; Gopalan B; Na J; Hazen SL; DiDonato JA
Oncotarget; 2020 May; 11(19):1777-1796. PubMed ID: 32477466
[TBL] [Abstract][Full Text] [Related]
8. N-terminal eGFP-tagging of rabbit apolipoprotein A-I decreases expression and impairs cholesterol-efflux activity.
Wacker BK; Bi L; Liu L; Sorci-Thomas MG; Ng P; Palmer DJ; Tang C; Dichek DA
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 May; 1868(5):159301. PubMed ID: 36858111
[No Abstract] [Full Text] [Related]
9. The effect of two types of diet on apoptosis indexes, lipid profile and histopathological outcome in acute kidney injury during exercise.
Sabet N; Soltani Z; Khaksari M; Iranpour M; Afshar RM; Mehdiabadi FM; Raji-Amirhasani A
BMC Nephrol; 2022 Sep; 23(1):315. PubMed ID: 36123655
[TBL] [Abstract][Full Text] [Related]
10. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B
Hrubša M; Siatka T; Nejmanová I; Vopršalová M; Kujovská Krčmová L; Matoušová K; Javorská L; Macáková K; Mercolini L; Remião F; Máťuš M; Mladěnka P; On Behalf Of The Oemonom
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276844
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Intervention to Modulate HDL: What Do We Target?
Woudberg NJ; Pedretti S; Lecour S; Schulz R; Vuilleumier N; James RW; Frias MA
Front Pharmacol; 2017; 8():989. PubMed ID: 29403378
[TBL] [Abstract][Full Text] [Related]
12. High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus.
He Y; Kothari V; Bornfeldt KE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):e10-e16. PubMed ID: 29367232
[No Abstract] [Full Text] [Related]
13. Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.
Tuteja S; Wang L; Dunbar RL; Chen J; DerOhannessian S; Marcovina SM; Elam M; Lader E; Rader DJ
Pharmacogenet Genomics; 2017 Aug; 27(8):285-293. PubMed ID: 28628560
[TBL] [Abstract][Full Text] [Related]
14. Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.
Batuca JR; Amaral MC; Favas C; Paula FS; Ames PRJ; Papoila AL; Delgado Alves J
Br J Clin Pharmacol; 2017 May; 83(5):1002-1010. PubMed ID: 27891663
[TBL] [Abstract][Full Text] [Related]
15. Dietary Niacin Supplementation Suppressed Hepatic Lipid Accumulation in Rabbits.
Liu L; Li C; Fu C; Li F
Asian-Australas J Anim Sci; 2016 Dec; 29(12):1748-1755. PubMed ID: 27004817
[TBL] [Abstract][Full Text] [Related]
16. High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.
Cimmino G; Ciccarelli G; Morello A; Ciccarelli M; Golino P
Transl Med UniSa; 2015; 12():29-40. PubMed ID: 26535185
[TBL] [Abstract][Full Text] [Related]
17. Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction.
Mohseni M; Vafa MR; Hajimiresmail SJ; Zarrati M; Rahimi Forushani A; Bitarafan V; Shidfar F
Iran Red Crescent Med J; 2014 Oct; 16(10):e16433. PubMed ID: 25763201
[TBL] [Abstract][Full Text] [Related]
18. Neurorestorative therapy for stroke.
Chen J; Venkat P; Zacharek A; Chopp M
Front Hum Neurosci; 2014; 8():382. PubMed ID: 25018718
[TBL] [Abstract][Full Text] [Related]
19. Niacin, an old drug with a new twist.
Song WL; FitzGerald GA
J Lipid Res; 2013 Oct; 54(10):2586-94. PubMed ID: 23948546
[TBL] [Abstract][Full Text] [Related]
20. Niacin Ameliorates Lipid Disturbances due to Glucocorticoid Administration in Rats.
Safaei N; Shomali T; Taherianfard M
Iran J Basic Med Sci; 2012 Jul; 15(4):997-1002. PubMed ID: 23493662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
